Key Takeaways
- •Semax is ACTH(4-7) extended with Pro-Gly-Pro, sequence Met-Glu-His-Phe-Pro-Gly-Pro, with CAS 80714-61-0, formula C37H51N9O10S and an average mass of 813.9 g/mol. Only four of its seven residues derive from ACTH.
- •Selank is tuftsin extended with the same Pro-Gly-Pro, sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, with CAS 129954-34-3, formula C33H57N11O9 and an average mass of 751.9 g/mol.
- •The shared Pro-Gly-Pro tail is the design. Both compounds take a short natural fragment and append the same three residues, a modification associated with resistance to peptidase degradation.
- •Adamax has no public registry record. No PubChem entry answers to the name, and the catalogue carries no CAS number, formula or molecular weight for it, which places it in a different verification category from the other two.
- •Neither is FDA-approved, and the 2026 US record on Semax is split. Both are registered pharmaceuticals in Russia, which carries no standing in the United States. FDA reviewers concluded in July 2026 that the evaluation criteria "weigh against" placing semax free base or semax acetate on the 503A list; the advisory committee voted the other way, and HHS's October 2026 draft policy includes Semax.
- •The primary literature is predominantly Russian-language and rodent-based, concentrated on gene and protein expression endpoints rather than clinical outcomes.
Summary
Semax and Selank are two unrelated short natural fragments, one from ACTH and one from the immune peptide tuftsin, each extended with the same Pro-Gly-Pro tail that slows breakdown by peptidases. Both have registry entries, published formulas and masses, so a lot can be checked against fixed reference values. Adamax has none of those, so its identity rests entirely on the supplying laboratory's own reference standard. In the United States, FDA reviewers recommended against listing Semax for compounding in July 2026, the advisory committee voted the other way, and the October 2026 HHS draft policy includes it; none of the three is FDA-approved.
Semax and Selank are sold as a matched pair, one for focus and one for calm. The framing is marketing shorthand, and it hides the one fact that explains both molecules: they are two unrelated natural fragments carrying the same three-residue tail. Adamax, sold beside them, cannot be checked the way either of them can. And the US position on all three moved in 2026, in a direction most pages have not caught up with: FDA reviewers recommended against adding Semax to the compounding list in July, and HHS published a draft policy in October that includes it anyway.
This guide covers what each of the three actually is, the design logic Semax and Selank share, what FDA reviewers concluded about Semax in July 2026, what the October 2026 HHS policy does and does not do, what the published work measured, and why one of the three sits in a different verification category. It is written for laboratory and in-vitro research procurement. It reports what published studies recorded in cell and animal models because that is the public evidence base, and it contains no dosing, administration or human-use guidance, and none should be inferred.
What the Three Are
| Property | Semax | Selank | Adamax |
|---|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Not publicly established |
| Parent fragment | ACTH(4-7) | Tuftsin, Thr-Lys-Pro-Arg | Reported as ACTH-related |
| Residues | 7 | 7 | Not publicly established |
| CAS number | 80714-61-0 | 129954-34-3 | None on file |
| Molecular formula | C37H51N9O10S | C33H57N11O9 | None on file |
| Average mass | 813.9 g/mol | 751.9 g/mol | None on file |
| Monoisotopic mass | 813.3480 Da | 751.4341 Da | Not publicly established |
| PubChem record | CID 9811102 | CID 11765600 | None under this name |
The Semax and Selank values agree with those PubChem records, and the Semax figures also match the FDA's own July 2026 briefing document, which records CAS 80714-61-0, C37H51N9O10S and 813.93 g/mol for the free base, and a separate acetate salt at C39H55N9O12S and 874.0 g/mol. The Adamax column is empty because the information does not exist publicly, not because it has not been looked up, and Volta's own product page records the same three absences rather than printing a figure it cannot support.

The Pro-Gly-Pro Tail Is the Whole Design
Read the two sequences next to each other and the pattern is immediate. Semax is Met-Glu-His-Phe followed by Pro-Gly-Pro. Selank is Thr-Lys-Pro-Arg followed by Pro-Gly-Pro. Two different four-residue natural fragments, one identical three-residue addition.
The parents are unrelated. Met-Glu-His-Phe is residues 4 to 7 of adrenocorticotropic hormone. Thr-Lys-Pro-Arg is tuftsin, a tetrapeptide derived from the immunoglobulin G heavy chain. They come from different proteins and different physiological systems.
What they share is the problem the tail solves. A four-residue peptide in plasma is cleared almost immediately by aminopeptidases and carboxypeptidases. Proline is the residue that interferes with this: most peptidases cut poorly next to a proline, and a C-terminal Pro-Gly-Pro motif is a well-known way to slow enzymatic degradation of a short peptide. Appending it extends how long the active fragment survives without altering the fragment itself.
So these are not two analogues of one compound, and they are not members of one pharmacological class. They are two applications of one chemical trick to two unrelated starting materials. Grouping them as "Russian nootropic peptides" describes their provenance and tells you nothing about their chemistry; grouping them by the Pro-Gly-Pro strategy describes what was actually done to make them.
"ACTH(4-10) analogue" or "ACTH(4-7) plus Pro-Gly-Pro"?
Both descriptions are in circulation and both are defensible, which is worth stating rather than picking a side. The FDA's own 2026 review calls Semax "a synthetic heptapeptide analog of the ACTH 4-10 fragment" and then immediately notes that the two "differ with respect to the three amino acids in the C-terminal domain." PubChem's synonym record takes the other route and records it as ACTH(4-7) plus Pro-Gly-Pro.
The sequence settles what each description means. ACTH(4-10) is Met-Glu-His-Phe-Arg-Trp-Gly. Semax is Met-Glu-His-Phe-Pro-Gly-Pro. They are both seven residues and they share the first four, so "analogue of ACTH(4-10)" is accurate as a statement of lineage and misleading if read as a statement of composition: the last three residues are not hormone at all, they are the stabilising tail. Anyone comparing a certificate against a sequence should use the sequence, not the lineage.
Adamax Sits in a Different Category
Adamax is described as an adamantane-conjugated analogue related to the ACTH fragment family, carrying a bulky cage hydrocarbon intended to raise lipophilicity relative to the unmodified peptide. The rationale is plausible and the compound is real enough to be sold. The problem is that none of it can be checked.
There is no PubChem record under the name. There is no CAS number in general use. No molecular formula or mass is published, which means there is no reference value for a laboratory to measure a lot against, and no figure a buyer can compare a certificate to. The indexed literature on the compound specifically is sparse compared with the hundreds of papers on its parent compounds.
That is a verification gap rather than a safety claim, and it is worth stating plainly rather than filling with a plausible-looking number. A mass spectrometric identity check works by comparing a measured mass against an expected one. With no established expected mass, the check cannot be performed in the usual way, and the identity claim rests entirely on the synthesizing laboratory's own reference material and documentation. For an exploratory material that may be acceptable; what is not acceptable is presenting it as equivalently characterized to Semax or Selank, which have registry entries, published formulas and decades of literature.
Anyone sourcing Adamax should ask what reference standard the identity was established against and treat the compound as exploratory rather than well-characterized.
A related point applies to the Semax variants circulating in this market. N-acetyl Semax amidate, for instance, does have a PubChem record (CID 172638603, C39H54N10O10S, average mass 855.0 g/mol), so it is checkable even though it is a modified form. The presence or absence of a registry record is not about how novel a compound is; it is about whether anyone can verify what is in the vial.
Status in the United States
| Question | Semax | Selank | Adamax |
|---|---|---|---|
| FDA-approved drug product | No | No | No |
| On the 503A Bulks List | No | No | No |
| FDA reviewers' recommendation, July 2026 | Against listing | Not reviewed | Not reviewed |
| In the October 2026 HHS draft policy | Yes, as Semax (free base) per published summaries | No | No |
| Registered elsewhere | Yes, Russia | Yes, Russia | Not established |
| Supplied as | Research material, in vitro use only | Research material, in vitro use only | Research material, in vitro use only |
Neither Semax nor Selank is an approved drug product in the United States, and none of the three has ever been. Both appear in the FDA's published list of bulk substances that were nominated for compounding and later withdrawn, where the agency records that compounded drugs containing semax (heptapeptide) and selank acetate (TP-7) may pose an immunogenicity risk because of the potential for aggregation and peptide-related impurities, and that it lacks the information to know whether either would cause harm in people.
What FDA reviewers concluded about Semax in July 2026
Semax went before the FDA's Pharmacy Compounding Advisory Committee on 24 July 2026. The agency's briefing document is unusually direct: after evaluating the physicochemical characterisation, historical use, effectiveness and safety, FDA staff wrote that "the evaluation criteria weigh against placing both semax (free base) and semax acetate on the list of bulk drug substances that can be used to compound drug products."
Their stated reasons are worth reading, because they are about the material rather than about the idea:
- Characterisation. Both forms were judged "not well-characterized," on two grounds: naming conventions that do not follow INN, IUPAC or USAN standards, and the absence of quality-control data on impurities, aggregates, bacterial endotoxins and microbial bioburden in the public literature and in the certificates supplied.
- Immunogenicity. FDA records a specific concern about aggregation and peptide-related impurities in finished liquid products.
- Evidence. The reviewers noted that much of the supporting literature is published in Russian, that some cited reviews provide only animal references, and that the human references they could follow were in healthy adults or not in English.
- A pharmacology flag. The review notes that in mice, semax "potentiated amphetamine-induced dopamine release in the striatum," and says that is concerning because increased striatal dopaminergic tone is a response typically produced by drugs of abuse.
The committee nevertheless voted to recommend adding Semax, and on 30 October 2026 HHS published a draft enforcement discretion policy covering 503A compounding with six peptides, with published summaries of its appendix listing Semax free base among them. That policy is a draft, is not binding, does not add anything to the 503A Bulks List, and covers compounding by state-licensed pharmacies and physicians rather than research-use material. The same sequence of events, from a different compound's point of view, is set out in what is KPV peptide.
The Russian registration, and what it is worth here
Both compounds are registered pharmaceuticals in Russia, where Semax has been in use since the 1990s; the FDA's review records it as a registered drug there, supplied as 0.1% and 1% solutions. That is a genuine regulatory fact and one of the easiest to misuse. A registration in one jurisdiction carries no legal standing in another and implies nothing about what the FDA would conclude from the same dossier. Registration regimes differ in the evidence they require, and the supporting literature is largely in Russian-language journals thinly represented in the databases Western regulators rely on, so much of the evidence is hard to check from outside Russia.
What the Published Research Measured
The primary work on both compounds is rodent and cell-based, and concentrates on expression endpoints rather than behavioral or clinical outcomes. That is a meaningful distinction: measuring that a gene's transcript level rose is not the same as measuring that anything happened to the animal, still less to a person.
Semax, in its own terms:
- A 2006 paper in the Journal of Neurochemistry reported that Semax binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain (PMID 16635254). Specific binding plus a protein-level change is the strongest form of evidence in this literature.
- A 2006 paper in Brain Research reported regulation of BDNF and trkB expression in the rat hippocampus (PMID 16996037).
- A 2007 paper in Neuroscience Letters examined neurotrophin gene expression in rat brain under Semax (PMID 17353092), and a 2010 paper in the Journal of Molecular Neuroscience compared the temporal dynamics of NGF and BDNF gene expression across hippocampus, frontal cortex and retina (PMID 19662538).
- A 2021 paper in Neuropeptides examined behavioral and neurochemical endpoints following early-life exposure in rats (PMID 33418449).
Selank, in its own terms:
- A 2011 paper in Genetika reported changes in expression of chemokine and cytokine genes and their receptors in response to Selank and its fragments (PMID 21786679), which is an immunological endpoint consistent with its tuftsin parentage.
- A 2019 paper in the Bulletin of Experimental Biology and Medicine reported regulation of BDNF content in rat hippocampus and prefrontal cortex in an ethanol memory-impairment model (PMID 31625062), and a 2022 paper in the same journal examined aversive signs of morphine withdrawal in rats (PMID 36322304).
- A 2021 review in the Journal of Clinical Pharmacology discusses it among agents acting on GABA receptors (PMID 34396551).
- A 2020 paper in Doklady Biological Sciences applied a functional connectomic approach to the effects of both Selank and Semax (PMID 32342318), one of the few papers treating the two together.

Important note: no finding for Semax, Selank or Adamax has been established in a human clinical trial published in the databases used here, and none of the three holds a US marketing authorization.

How to Verify a Lot
For Semax and Selank, the reference values exist, so use them. Semax has a monoisotopic mass of 813.3480 Da and Selank 751.4341 Da. A mass spectrometric identity check against a reference standard, compared to those figures, is what confirms the molecule is the one named. The methods are set out in what actually proves a peptide sequence.
A purity figure is weak evidence for a seven-residue peptide. Chromatographic purity detects truncation and deletion impurities, and a seven-residue chain has few ways to produce them, so high purity is easy to achieve and distinguishes little. For Semax specifically, the single methionine at position 1 is oxidation-labile, and an oxidized species appears as a plus 16 dalton mass difference rather than as a purity problem.
Selank is proline-rich and basic. Three of its seven residues are proline and it carries both a lysine and an arginine, so it is strongly basic and supplied as a salt. Net peptide content is the figure that tells you how much peptide the powder holds, and a purity ratio does not answer it.
For Adamax, ask what the identity was established against. With no published formula or mass, there is no public reference value, so the question is which reference standard the laboratory used and what method established the identity. Treat an answer of "purity by HPLC" alone as not having addressed identity at all. Laboratories that can be commissioned independently are listed under independent testing laboratories.
Check the three things that make a certificate checkable:
- The laboratory is named, with its report number.
- The lot number on the document matches the vial in your hand.
- The laboratory publishes a verification page where the report number can be looked up independently.
A certificate that names no laboratory, or whose lot number matches nothing on the container, is a document about some other material. Volta publishes its certificates as page images in its published certificate archive with the issuing laboratory's own verification link, and a certificate for the batch you receive is available on request. Those reports carry both HPLC and mass spectrometry results.
The Combination Vial
Semax, Selank and Adamax are each stocked as 10 mg vials, and the two characterized compounds also appear together in a 20 mg multi-component vial. The compound hubs are Semax and Selank, and a different kind of material from the same Russian clinical tradition, a hydrolysate rather than a defined peptide, is covered in Cerebrolysin in Canada.
That combination holds two peptides from unrelated parent proteins addressing different systems, joined by nothing except the Pro-Gly-Pro stabilizing motif and a shared research history. It is not a stronger version of either one.
A composition certificate for such a vial measures each compound separately, reporting a purity and a net peptide content per component and no single purity for the vial, because the vial is not one substance. This is covered in detail in the analytical tradeoffs of a blend. The 20 mg on the label is divided between the two, so neither compound's quantity is the headline figure, and the per-component masses are on the certificate rather than the label. The two are close enough in mass, 813.9 against 751.9 g/mol, that an equal mass split is also close to an equal molar split, which is unusual on this shelf and worth noting only because it is so rarely true elsewhere.
Frequently Asked Questions
Is Semax an ACTH(4-10) analogue?
Not precisely. Semax is Met-Glu-His-Phe-Pro-Gly-Pro, which is ACTH(4-7) extended with Pro-Gly-Pro. ACTH(4-10) is Met-Glu-His-Phe-Arg-Trp-Gly, so the two share only their first four residues and differ in the last three. Both are seven residues long, which is likely why the description persists.
What is Selank made from?
Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro: tuftsin, a tetrapeptide from the immunoglobulin G heavy chain, extended with Pro-Gly-Pro. Its CAS number is 129954-34-3 and its average mass is 751.9 g/mol.
Why do Semax and Selank share their last three residues?
Because the Pro-Gly-Pro tail is a stabilizing modification rather than part of either parent sequence. Proline interferes with most peptidases, so a C-terminal Pro-Gly-Pro slows enzymatic degradation of a short peptide. The two compounds apply the same technique to unrelated starting fragments.
Is Semax FDA-approved?
No. Semax is not an approved drug product in the United States and is not on the 503A Bulks List. FDA reviewers recommended against listing it in July 2026; the advisory committee recommended adding it; and HHS's October 2026 draft policy, which is not binding and not an approval, includes it.
Is Selank FDA-approved?
No. Selank is not approved in the United States, is not on the 503A Bulks List, and is not among the six peptides in the October 2026 HHS draft policy. It appears in the FDA's list of substances nominated for compounding and later withdrawn.
Are Semax and Selank approved anywhere?
Both are registered pharmaceuticals in Russia, where FDA's review records Semax as supplied in 0.1% and 1% solutions. A registration in one jurisdiction carries no standing in another.
Can Semax and Selank be used together?
They are sold together, and one published paper applies a functional connectomic approach to both. No controlled human trial has tested the combination, so there is no evidence base for it either way.
Which is which: Semax for focus, Selank for calm?
That is how the market describes them, based on the research traditions around each: Semax has been studied mainly for neurotrophic and cognitive endpoints, Selank for anxiety-related and immune endpoints consistent with its tuftsin parentage. Both characterisations come from animal and small human studies, not from controlled comparative work.
Why can Adamax not be verified like the other two?
Because no public registry record exists for it. There is no PubChem entry under the name, no CAS number in general use, and no published molecular formula or mass, so there is no reference value to compare a measured mass against. The identity claim rests on the synthesizing laboratory's own reference material, which should be asked about explicitly.
Is a purity percentage meaningful for a seven-residue peptide?
Only weakly. Chromatographic purity mainly detects synthesis-related impurities such as truncated sequences, and a seven-residue chain produces few of them, so a high figure is easy to achieve. Identity by mass spectrometry against a reference standard, and net peptide content, are the more informative measurements.
Sources
- PubChem Compound Summary, CID 9811102 (Semax). National Library of Medicine. Sequence synonym recorded as MEHFPGP and as ACTH (4-7), Pro-Gly-Pro; CAS number, formula, average mass and monoisotopic mass as cited above.
- PubChem Compound Summary, CID 11765600 (Selank). National Library of Medicine. Sequence synonym recorded as Thr-Lys-Pro-Arg-Pro-Gly-Pro; values as cited above.
- PubChem Compound Summary, CID 172638603 (N-Acetyl Semax Amidate). National Library of Medicine. Formula C39H54N10O10S, average mass 855.0 g/mol.
- PubChem: no compound record returned for the names "Adamax" or "adamax peptide", checked 6 November 2026.
- US Food and Drug Administration. FDA Evaluation of Semax (Free Base) and Semax Acetate for Inclusion on the 503A Bulk Drug Substances List. Briefing document, Pharmacy Compounding Advisory Committee, 23-24 July 2026.
- US Food and Drug Administration. "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks," including the list of substances nominated but withdrawn. Content current as of 22 April 2026.
- US Department of Health and Human Services. "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." Federal Register, 30 October 2026, FR Doc. 2026-22192.
- Health Canada Drug Product Database, active-ingredient searches for semax and for selank: no result returned, checked 6 November 2026.
- Journal of Neurochemistry. 2006. "Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain." PMID 16635254.
- Brain Research. 2006. "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." PMID 16996037.
- Neuroscience Letters. 2007. "Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10." PMID 17353092.
- Journal of Molecular Neuroscience. 2010. "Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action." PMID 19662538.
- Neuropeptides. 2021. "Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats." PMID 33418449.
- Genetika. 2011. "Changes in expression of the genes for chemokines, cytokines, and their receptors in response to selank and its fragments." PMID 21786679.
- Bulletin of Experimental Biology and Medicine. 2019. "Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats." PMID 31625062.
- Bulletin of Experimental Biology and Medicine. 2022. "Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats." PMID 36322304.
- Journal of Clinical Pharmacology. 2021. "Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank." PMID 34396551.
- Doklady Biological Sciences. 2020. "Functional Connectomic Approach to Studying Selank and Semax Effects." PMID 32342318.
Note on the titles above: two of the cited papers carry "ACTH(4-10)" in their own titles, which is the convention this post argues is imprecise. The titles are quoted as published.

